Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
HUTCHMED (China) Limited ( (HK:0013) ) has issued an announcement.
HUTCHMED (China) Limited has announced it will release its final results for the fiscal year 2024 on March 19, 2025. The announcement will be followed by a conference call and webcast, providing insights into the company’s performance, likely influencing stakeholder perceptions and potentially impacting the company’s market positioning.
More about HUTCHMED (China) Limited
HUTCHMED (China) Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for cancer and immunological diseases. The company has successfully marketed three medicines in China, with one gaining approval in the US, Europe, and Japan.
YTD Price Performance: -8.09%
Average Trading Volume: 49,176
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £1.89B
For a thorough assessment of 0013 stock, go to TipRanks’ Stock Analysis page.
